Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: A potential treatment for lymphangioleiomyomatosis

International Journal of Cancer

Volumn 130, Issue 6, 2012, Pages 1420-1429

  Makovski, Victoria ^a   Haklai, Roni ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

ELT3; LAM; Rheb; salirasib; TSC2

Indexed keywords

GUANOSINE TRIPHOSPHATASE; RAS PROTEIN; RHEB PROTEIN; SALIRASIB; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; LYMPHANGIOLEIOMYOMATOSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; TUBEROUS SCLEROSIS; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE; FARNESOL; LYMPHANGIOLEIOMYOMATOSIS; LYMPHOCYTES, NULL; MICE; MICE, NUDE; MONOMERIC GTP-BINDING PROTEINS; MUTATION; NEUROPEPTIDES; PHOSPHORYLATION; RAS PROTEINS; RATS; RIBOSOMAL PROTEIN S6 KINASES; SALICYLIC ACIDS; TUMOR SUPPRESSOR PROTEINS;

EID: 84856111964     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26139     Document Type: Article

References (34)

1. Krymskaya VP,. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis. Proc Am Thorac Soc 2008; 5: 119-26.
2. Goncharova EA, Krymskaya VP,. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem 2008; 103: 369-82. (Pubitemid 351171909)
3. Taveira-DaSilva AM, Steagall WK, Moss J,. Lymphangioleiomyomatosis. Cancer Control 2006; 13: 276-85. (Pubitemid 44600939)
4. Johnson SR,. Lymphangioleiomyomatosis. Eur Respir J 2006; 27: 1056-65. (Pubitemid 44911122)
5. Castro AF, Rebhun JF, Clark GJ, Quilliam LA,. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003; 278: 32493-6. (Pubitemid 37055685)
6. Aspuria PJ, Tamanoi F,. The Rheb family of GTP-binding proteins. Cell Signal 2004; 16: 1105-12. (Pubitemid 38900513)
7. Buerger C, DeVries B, Stambolic V,. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem Biophys Res Commun 2006; 344: 869-80.
8. Hancock JF,. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 2003; 4: 373-84. (Pubitemid 36565569)
9. Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F,. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 2005; 6: 301-23. (Pubitemid 40667797)
10. Shaw RJ, Cantley LC,. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30. (Pubitemid 44050136)
11. Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y, Ben Baruch G, Kloog Y,. Dislodgment and accelerated degradation of Ras. Biochemistry 1998; 37: 1306-14.
12. Goldberg l, Haklai R, Bauer V, Heiss A, Kloog Y,. New derivatives of farnesyltiosalicylic acid (salirasib) for cancer treatment: farnesyltiosalicylamide inhibits tumor growth in nude mice model. J Med Chem 2009; 52: 197-205.
13. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA, Jr, Krymskaya VP,. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002; 277: 30958-67. (Pubitemid 34970798)
14. Elad-Sfadia G, Haklai R, Ballan E, Gabius HJ, Kloog Y,. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 2002; 277: 37169-75.
15. de Rooij J, Bos JL,. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997; 14: 623-5. (Pubitemid 27090966)
16. Biran A, Brownstein M, Haklai R, Kloog Y,. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int J Cancer 2011; 128: 691-701.
17. Castro AF, Rebhun JF, Quilliam LA,. Measuring Ras-family GTP levels in vivo-running hot and cold. Methods 2005; 37: 190-6. (Pubitemid 41587428)
18. Goldberg L, Kloog Y,. A Ras inhibitor tilts the balance between Rac and Rho and blocks PI3-kinase-dependent glioblastoma cell migration. Cancer Res 2006; 66: 11709-17. (Pubitemid 46094183)
19. Walker CL, Hunter D, Everitt JI,. Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003; 38: 349-56. (Pubitemid 37466936)
20. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, Henske EP,. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 2004; 279: 29930-7. (Pubitemid 38937912)
21. Howe SR, Gottardis MM, Everitt JI, Goldsworthy TL, Wolf DC, Walker C,. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol 1995; 146: 1568-79.
22. Marom M, Haklai R, Ben Baruch G, Marciano D, Egozi Y, Kloog Y,. Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid. J Biol Chem 1995; 270: 22263-70.
23. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ, Cheng JQ,. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 2002; 277: 35364-70.
24. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP,. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 2002; 21: 8470-6. (Pubitemid 36054887)
25. Codeluppi S, Svensson CI, Hefferan MP, Valencia F, Silldorff MD, Oshiro M, Marsala M, Pasquale EB,. The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord. J Neurosci 2009; 29: 1093-104.
26. Berven LA, Willard FS, Crouch MF,. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 2004; 296: 183-95. (Pubitemid 38624640)
27. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y,. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2008; 61: 89-96. (Pubitemid 47512630)
28. Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ,. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene 2010; 29: 380-91.
29. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, Blenis J,. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 2007; 282: 14056-64. (Pubitemid 47100467)
30. Sampson JR,. Therapeutic targeting of mTOR in tuberous sclerosis. Biochem Soc Trans 2009; 37: 259-64.
31. Elad G, Paz A, Haklai R, Marciano D, Cox A, Kloog Y,. Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1999; 1452: 228-42.
32. Cox AD, Der CJ,. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002; 1: 599-606.
33. Hancock JF, Parton RG,. Ras plasma membrane signalling platforms. Biochem J 2005; 389: 1-11. (Pubitemid 40978001)
34. Rotblat B, Ehrlich M, Haklai R, Kloog Y,. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol 2008; 439: 467-89.